From Paper to Clinic, Episode 7: GLP-1s and idiopathic intracranial hypertension

Welcome to From Paper to Clinic, a podcast focused on evidence-based eye care and real-world clinical decision-making, hosted by Hamza Shah, OD, MS, FAAO, a faculty member at the University of Houston College of Optometry. His work spans clinical patient care, education, and mentoring, and his clinical interests include ocular disease, dry eye, perioperative care, and, above all, the challenge of translating information into meaningful patient outcomes.

In Episode 7 of From Paper to Clinic, "GLP-1 Receptor Agonists and Idiopathic Intracranial Hypertension," Leonard Messner, OD, FAAO, vice president and professor of optometry at the Illinois College of Optometry, joins the show to explore what a landmark randomized trial on exenatide reveals about the underlying mechanisms of IIH—and what it means for how optometrists manage the disease today.

GLP-1 receptor agonists have reshaped obesity medicine, but their potential in IIH has less to do with weight loss than with the basic biology of intracranial pressure. The choroid plexus is dense with GLP-1 receptors, and animal studies have shown that GLP-1 agonists could meaningfully suppress cerebrospinal fluid production. The Mitchell et al trial took that preclinical signal directly to human subjects: 15 women with active IIH received either subcutaneous exenatide or placebo for 12 weeks, with intracranial pressure measured via telemetric catheters at 2.5 hours, 24 hours, and 3 months. The results were striking—exenatide reduced ICP by approximately 5 to 6 centimeters of water pressure at all three time points, and it did so quickly. A measurable reduction was already present at the 2.5-hour measurement.

The finding that the benefit appeared independent of weight loss was the study's most clinically provocative result. At 3 months, patients had not meaningfully changed their body weight—yet intracranial pressure remained significantly lower throughout. For a disease historically managed through the slow, difficult work of sustained weight loss alongside acetazolamide, that distinction matters. It suggests GLP-1 agents may act directly on ICP physiology rather than through metabolic effects, opening the possibility that they could benefit a broader range of patients, including those who struggle most with weight management.

Evidence has continued to accumulate since that 2023 trial. A subsequent retrospective study examining more than 1000 patients with IIH found that those on GLP-1 agonists showed significant improvements in papilledema, headaches, and visual function and were less likely to require surgical intervention for ICP management. The retrospective design—drawing from a billing database—limits the strength of those conclusions, but the directional signal aligns with the mechanism and the RCT data. Messner is cautious about abandoning established therapies: acetazolamide remains well-supported by the IIH Treatment Trial for early disease, and the potential risk of non-arteritic anterior ischemic optic neuropathy with GLP-1 agents warrants attention. But for patients who cannot tolerate acetazolamide or topiramate, or who have struggled with weight management programs, GLP-1 agonists represent a more realistic path to the outcomes optometrists want to see.

For ODs managing or comanaging IIH, Messner's diagnostic framework is as instructive as the pharmacology. He emphasizes the case history, not just current BMI, but the trajectory of weight gain—and the 2 symptoms he drills down on above all others: chronic daily headaches and synchronous pulsatile tinnitus. OCT remains central, but not just for RNFL thickness—the morphology of the optic nerve on B-scan, specifically the inward displacement of Bruch's membrane complex at the lamina cribrosa, is among the most clinically meaningful findings. So is the ganglion cell complex, which he treats as the critical indicator of how much time the clinician has. "It's the glaucoma of the brain," he notes of IIH—progressive, trackable, and consequential in ways that only become clear with consistent visual field monitoring.

The paper inspiring this discussion is "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial," by Mitchell and colleagues, published in Brain.

Do you want to only listen to this episode? Check out the audio player below.

Episode 8 is coming on Monday, October 5, 2026, at 8 AM ET

The eighth episode of From Paper to Clinic debuts in early October and features Cory Lappin, OD, who focuses on dynamic muscle stimulation of the periorbital area for blinking in dry eye. Listeners are invited to join the conversation as the series explores how evidence moves––from paper to clinic.